Aldeyra Therapeutics

AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a US-based biopharmaceutical company, to acquire a development, manufacturing, and commercialization license for the reactive aldehyde species (RASP) modulator, reproxalap. The agreement grants AbbVie co-exclusive rights in the US and exclusive rights in all other territories…